Ionis Pharmaceuticals inked a deal worth more than $700 million with pharma giant Roche to develop an antisense drug for the treatment of complement-mediated diseases.
Dr. Robert Redfield, the new head of the U.S. Centers for Disease Control and Prevention, boldly predicted in April 2018 that the AIDS epidemic can be defeated by 2025. Merck, Janssen and Gilead Sciences all released clinical data for HIV treatments that could make Redfield’s prediction a reality.
J&J agreed to develop and market Arrowhead Pharmaceuticals Inc.’s gene-silencing hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion.
Personalized medicine continues to grow in importance, and having the ability to monitor health data has proven to be a significant desire for people as the number of wearable devices continues to grow.
Rockville, Maryland-based Supernus Pharmaceuticals is acquiring Biscayne Neurotherapeutics, which is located in Miami.
Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.
The U.S. Food and Drug Administration cleared Cleveland-based SPR Therapeutics’ SPRING endura (single lead) and extensa (dual lead) Peripheral Nerve Stimulation Systems for controlling pain.
Novo Nordisk revealed that oral semaglutide achieved positive results in the PIONEER 5 study for the reduction of blood sugar levels and weight in adults with type 2 diabetes.
Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.
Amicus Therapeutics set an average price of $315,000 per year for the company’s newly approved Fabry disease treatment.
The U.S. Drug Enforcement Agency is readdressing cannabis following the regulatory approval of the first cannabinoid-based drug for the treatment of some epilepsy patients.
The U.S. FDA approved Alkermes plc’s Aristada Initio (aripiprazole lauroxil) as part of a combination treatment for schizophrenia.
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
DyAnsys Inc. announced that the U.S. Food and Drug Administration cleared the company’s auricular neurostimulation device, Drug Relief, to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics.
The U.S. Food and Drug Administration approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte, but declined to approve its higher and more lucrative dose.
Abbott received approval from the U.S. Food and Drug Administration for XIENCE Sierra, the newest generation of the gold-standard XIENCE everolimus-eluting coronary stent system.
Lilly’s Taltz Receives First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving Genital Area
Eli Lilly and Company announced that the U.S. Food and Drug Administration approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.
FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems
The U.S. Food and Drug Administration permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.
Britain’s healthcare watchdog NICE recommended Roche’s medicine Gazyvaro for previously untreated advanced follicular lymphoma patients after initially rejecting the medicine in 2017.
Novartis Receives FDA Approval for Cosentyx Label Update to Include Moderate to Severe Scalp Psoriasis
Novartis announced that the U.S. Food and Drug Administration approved a label update for Cosentyx (secukinumab), the first interleukin-17A antagonist cleared to treat moderate to severe plaque psoriasis, to include data in moderate to severe scalp psoriasis.